Home›Research›Compare›Ac-SDKP vs Angiotensin (1-7)
Peptide ComparisonAc-SDKP vs Angiotensin (1-7)
Ac-SDKP
N-acetyl-seryl-aspartyl-lysyl-proline
No providers listed yet
Angiotensin (1-7)
Ang-(1-7)
Half-life: ~9–10 sec (rat)
No providers listed yet
Ac-SDKP and Angiotensin (1-7) target different goals — Ac-SDKP for anti-fibrotic, Angiotensin (1-7) for cardiovascular protection. They're compared here for reference, not as direct substitutes.
Ac-SDKP
Evidence
Half-life
—
Angiotensin (1-7)
Evidence
Half-life
~9–10 sec (rat)
Ac-SDKP and Angiotensin (1-7) target different goals — Ac-SDKP for Tissue Repair, Angiotensin (1-7) for Longevity & Cellular. They're compared here for reference; there isn't a single “better” choice between them.
Ac-SDKP
Angiotensin (1-7)
Ac-SDKP
Device surface-functionalized ac-SDKP nanoassemblies accelerate endothelial recovery through dual anti-inflam…
Ac-SDKP Attenuates Silica-Induced Pulmonary Fibrosis by Inhibiting ALKBH1-Mediated m(6)A Demethylation of miR…
N-Acetyl-Seryl-Aspartyl-Lysyl-Proline: mechanisms of renal protection in mouse model of systemic lupus erythe…
Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis
Angiotensin (1-7)
The Effect of Angiotensin (1-7) on Serum Metabolomics in Obese Type 2 Diabetic Mice.
Perioperative Angiotensin-(1-7) for Postoperative Cognitive Vulnerability Following Coronary Artery Bypass Su…
Severe Acute Hypertension Causes Hemolysis With Release of PEP and ACE Inhibitor.
Neuroprotective effects of telmisartan in a harmaline-induced model of essential tremor: modulation of the re…
+11 more
About Ac-SDKP
Inhibits hematopoietic stem cell entry into S-phase. Blocks TGF-β1-mediated fibroblast activation, reducing collagen deposition. Promotes angiogenesis via VEGF upregulation. Regulated in vivo by ACE enzyme.
About Angiotensin (1-7)
Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Ac-SDKP
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Angiotensin (1-7)
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Where to source these peptides
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
Related Comparisons
Browse all peptides →Educational research tools — not medical advice.